CommercialCoverageMedium impact
Home Hemoglobin Testing Devices (CPB 0824, reviewed 2025-12-09)
Aetna·Hematology, Internal Medicine, Family Medicine +3 more·Medical Policy
Effective date
Dec 9, 2025
We identified it
Aug 18, 2026
Summary
Aetna has classified home hemoglobin testing devices as experimental, investigational, or unproven for managing chronic anemia and all other indications, effective immediately. This means claims for home hemoglobin testing will not be covered. Billing teams must deny or reject any claims submitted for these devices and communicate non-coverage to providers.
Action Required
By December 9, 2025: Billing team must immediately update billing system denial rules to automatically reject or deny all claims for home hemoglobin testing devices (no specific CPT/HCPCS code exists per policy). Notify all ordering providers in hematology, internal medicine, family medicine, and oncology practices that home hemoglobin testing is not covered under Aetna plans. Update denial templates to reference Aetna CPB 0824 and explain experimental/investigational status. For ICD-10 codes D50.0-D64.9 (anemias), flag any claims requesting home hemoglobin testing for automatic denial. Train billing and authorization staff that this device category is non-covered for ALL anemia indications including chronic anemia, iron deficiency anemia, and anemia related to HIV, renal failure, hepatitis C, or myelosuppressive chemotherapy. Failure to implement denial rules will result in claim denials on appeal and patient responsibility issues.